参麦注射液治疗急性脑梗死的临床效果

摘要
图/表
参考文献(27)
相关文章 (15)

全文: PDF (573 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨参麦注射液对急性脑梗死的治疗效果。方法回顾性分析2017年6月至2019年6月于北京中医药大学东直门医院脑病科一区治疗的急性脑梗死患者122例的临床资料，根据治疗方法将其分为治疗组（66例）和对照组（56例）。两组均随症给予抗血小板、降脂、降压、控制血糖等常规治疗，治疗组在常规治疗基础上给予参麦注射液静脉滴注；对照组给予丹红注射液静脉滴注，两组均治疗14 d。比较两组治疗前与治疗14 d后的美国国立卫生研究院脑卒中量表（NIHSS）评分及不良事件发生情况。结果治疗14 d后，两组NIHSS评分均较治疗前降低，且治疗组低于对照组，差异有统计学意义（P ＜ 0.05）。两组病因不明（UE）亚型NIHSS评分治疗前后比较，差异无统计学意义（P ＞ 0.05）。治疗14 d后，两组心源性栓塞（CS）、大动脉粥样硬化型（LAA）、穿支动脉疾病（PAD）、其他病因（OE）亚型NIHSS评分均较治疗前降低，差异有统计学意义（P ＜ 0.05），治疗组LAA亚型NIHSS评分低于对照组，差异有统计学意义（P ＜ 0.05），两组CS、PAD、OE、UE亚型NIHSS评分比较，差异无统计学意义（P ＞ 0.05）。两组在治疗过程中均未发现明显不良反应。结论参麦注射液能够有效改善急性脑梗死患者神经功能缺损程度，其对LAA亚型脑梗疗效明显优于丹红注射液，在其他亚型中与丹红注射液作用相似。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵子珺杨保林杨俊行吕静敏张华马大勇高颖卫景沛

关键词 ：参麦注射液, 急性脑梗死, 中国缺血性卒中分型, 神经功能缺损

Abstract：Objective To investigate the therapeutic effect of Shenmai Injection on acute cerebral infarction. Methods Retrospective analysis was performed on the clinical data of 122 patients with acute cerebral infarction who were treated in the first area of the Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine from June 2017 to June 2019. According to the treatment methods, the patients were divided into treatment group (66 cases) and control group (56 cases). Both groups were given conventional treatment such as antiplatelet, lipid-lowering, hypotensive, and glycemic control, while the treatment group was given intravenous infusion of Shenmai Injection on the basis of conventional treatment. The control group was given Danhong Injection intravenously, and both groups were treated for 14 days. National Institutes of health stroke scale (NIHSS) scores and the incidence of adverse events were compared between the two groups before and after 14 days of treatment. Results After 14 days of treatment, the NIHSS scores in both groups were lower than that before treatment, and the treatment group were lower than the control group, with statistical significance (P ＜ 0.05). There was no significant difference in unknown etiology (UE) subtype NIHSS scores between the two groups before and after treatment (P ＞ 0.05). After 14 days of treatment, NIHSS scores of cardioembolism (CS), large-artery atherosclerosis (LAA), penetrating artery disease (PAD) and other etiology (OE) subtypes in both groups were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). The NIHSS score of LAA subtype in the treatment group was lower than that in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the NIHSS scores of CS, PAD, OE and UE subtypes between the two groups (P ＞ 0.05). No obvious adverse reactions were found in both groups during the treatment. Conclusion Shenmai Injection can effectively improve the degree of neurological impairment in patients with acute cerebral infarction, and its effect on LAA subtype cerebral infarction is obviously better than that of Danhong Injection, and its effect is similar to that of Danhong Injection in other subtypes.

Key words： Shenmai Injection Acute cerebral infarction Chinese ischemic stroke subclassification Neurological impairment

基金资助:国家重点研发计划（2017YFB1002304）；
国家自然科学基金资助项目（81704049）。

通讯作者: 卫景沛（1971.1-），男，硕士，副主任医师；研究方向：神经介入治疗及神经危重症。

作者简介: 赵子珺（1988.8-），女，中医学博士；研究方向：中医药防治脑病。

引用本文:

赵子珺杨保林杨俊行吕静敏张华马大勇高颖卫景沛. 参麦注射液治疗急性脑梗死的临床效果[J]. 中国医药导报, 2021, 18(20): 62-65.
ZHAO Zijun YANG Baolin YANG Junxing LYU Jingmin ZHANG Hua MA Dayong GAO Ying WEI Jingpei. Clinical effect of Shenmai Injection in the treatment of acute cerebral infarction. 中国医药导报, 2021, 18(20): 62-65.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I20/62